SuperworthAdvanced Biomed ADVB
- Market cap
- $5.2M
- PE
- n/m
- not a meaningful number
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- 0.4×
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- Q4 FY26 missing
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $169.2K | $188.4K | $313.5K | $209.1K | $181.7K+7% | $212.4K+13% | $220K−30% | $234.2K+12% | $236K+30% | $186.3K−12% | $243.2K+11% | n/a |
| SG&A | $271.1K | $462.9K | $431.9K | $495.5K | $338.3K+25% | $67.7K−85% | $347.5K−20% | $611.4K+23% | $287.9K−15% | $210.3K+211% | $276.6K−20% | $4M+551% |
| Pre-tax income | −$771.3K | −$145.3K | −$1.1M | −$809.4K | −$265.6K−66% | −$579.5K+299% | −$1.2M+13% | $675.6K | −$386.9K+46% | $7M | −$488.9K−59% | −$12.5M |
| Net income | −$771.3K | −$145.3K | −$1.1M | −$809.4K | −$265.6K−66% | −$907.9K+525% | −$1.4M+31% | −$701.6K−13% | −$386.9K+46% | $6.9M | −$488.9K−65% | $695K |
| −$0.80 | −$0.20 | −$1.00 | −$0.80 | −$0.20−75% | −$1.00+400% | −$1.35+35% | −$0.65−19% | −$0.40+100% | $6.20 | −$0.38−72% | $0.44 | |
| 1M | 1M | 1M | 1M | 1M+0% | 1M+0% | 1M+2% | 1.1M+8% | 1.1M+8% | 1.1M+8% | 1.3M+26% | 1.6M+45% |
R&D: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
SG&A: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Net income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q1 FY24 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY24 and Q1 FY25: share-days: the 6-month average less the second quarter's. Q4 FY24 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Advanced Biomed's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ADVBAdvanced Biomed | $5.2M | n/m | 3.0× | n/m | n/m | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| CKXCKX Lands | $21.5M | 7.4× | 32.6× | 31.0× | −17% | n/m | |
| MSGMMotorsport Games | $22.5M | 11.4× | 11.5× | 1.5× | +79% | 16.2% | |
| ATCHAtlasClear | $24M | 15.8× | 17.5× | 1.2× | +85% | 9.8% | |
| Peer median | $18.9M | 9.4× | 13.4× | 1.4× | −3% | 8.6% |
More on Advanced Biomed
Each number over time
Where it ranks
- #1of 202Healthcare stocks with the lowest EV/EBIT
- #1of 25Diagnostics and research stocks with the lowest EV/EBIT
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .